79 related articles for article (PubMed ID: 20124604)
21. Decreased serotonergic responsivity in platelets of drug-free patients with schizophrenia.
Yao JK; van Kammen DP; Moss HB; Sokulski DE
Psychiatry Res; 1996 Jul; 63(2-3):123-32. PubMed ID: 8878308
[TBL] [Abstract][Full Text] [Related]
22. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
23. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.
Krakowski MI; Czobor P; Citrome L; Bark N; Cooper TB
Arch Gen Psychiatry; 2006 Jun; 63(6):622-9. PubMed ID: 16754835
[TBL] [Abstract][Full Text] [Related]
24. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder.
Bilder RM; Goldman RS; Volavka J; Czobor P; Hoptman M; Sheitman B; Lindenmayer JP; Citrome L; McEvoy J; Kunz M; Chakos M; Cooper TB; Horowitz TL; Lieberman JA
Am J Psychiatry; 2002 Jun; 159(6):1018-28. PubMed ID: 12042192
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine vs haloperidol for treatment of schizophrenia.
Kunz M
JAMA; 2004 Mar; 291(9):1065; author reply 1065-6. PubMed ID: 14996768
[No Abstract] [Full Text] [Related]
26. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
27. Antipsychotic drug administration differentially affects [3H]muscimol and [3H]flunitrazepam GABA(A) receptor binding sites.
Skilbeck KJ; O'Reilly JN; Johnston GA; Hinton T
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):492-8. PubMed ID: 17976880
[TBL] [Abstract][Full Text] [Related]
28. Olanzapine vs haloperidol for treatment of schizophrenia.
Volavka J; Citrome L
JAMA; 2004 Mar; 291(9):1064; author reply 1065-6. PubMed ID: 14996765
[No Abstract] [Full Text] [Related]
29. Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia.
Schuhmacher A; Mössner R; Quednow BB; Kühn KU; Wagner M; Cvetanovska G; Rujescu D; Zill P; Möller HJ; Rietschel M; Franke P; Wölwer W; Gaebel W; Maier W
Pharmacogenet Genomics; 2009 Nov; 19(11):843-51. PubMed ID: 19794330
[TBL] [Abstract][Full Text] [Related]
30. Olanzapine vs haloperidol for treatment of schizophrenia.
Amin M; Shukla VS
JAMA; 2004 Mar; 291(9):1065; author reply 1065-6. PubMed ID: 14996767
[No Abstract] [Full Text] [Related]
31. Efficacy of olanzapine: an overview of pivotal clinical trials.
Beasley CM; Tollefson GD; Tran PV
J Clin Psychiatry; 1997; 58 Suppl 10():7-12. PubMed ID: 9265910
[TBL] [Abstract][Full Text] [Related]
32. Olanzapine vs haloperidol for treatment of schizophrenia.
Glazer WM
JAMA; 2004 Mar; 291(9):1064-5; author reply 1065-6. PubMed ID: 14996766
[No Abstract] [Full Text] [Related]
33. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Ishigooka J; Inada T; Miura S
Psychiatry Clin Neurosci; 2001 Aug; 55(4):403-14. PubMed ID: 11442893
[TBL] [Abstract][Full Text] [Related]
34. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
[TBL] [Abstract][Full Text] [Related]
35. Atypical antipsychotics, neurocognitive deficits, and aggression in schizophrenic patients.
Krakowski MI; Czobor P; Nolan KA
J Clin Psychopharmacol; 2008 Oct; 28(5):485-93. PubMed ID: 18794642
[TBL] [Abstract][Full Text] [Related]
36. [Economic comparison of olanzapine versus haloperidol in treatment of schizophrenia in France].
Le Pen C; Lilliu H; Allicar MP; Olivier V; Gregor KJ
Encephale; 1999; 25(4):281-6. PubMed ID: 10546082
[TBL] [Abstract][Full Text] [Related]
37. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
Tollefson GD; Sanger TM
Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
[TBL] [Abstract][Full Text] [Related]
38. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
39. Olanzapine treatment of residual positive and negative symptoms.
Buchanan RW; Ball MP; Weiner E; Kirkpatrick B; Gold JM; McMahon RP; Carpenter WT
Am J Psychiatry; 2005 Jan; 162(1):124-9. PubMed ID: 15625210
[TBL] [Abstract][Full Text] [Related]
40. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial.
Hamilton SH; Revicki DA; Genduso LA; Beasley CM
Neuropsychopharmacology; 1998 Jan; 18(1):41-9. PubMed ID: 9408917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
